Vera Therapeutics

Recent news

• Rating change
  Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Cuts Target Price to $43
  Market Newswire · 2026/7/13
• Company notice
  Vera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Oliger Christy J.
  SEC · 2026/5/27
• Company notice
  Takeda Pharmaceutical: The U.S. FDA has accepted Rusfertide's New Drug Application and designated it for Priority Review, with the potential to become a first-in-class treatment for polycythemia vera.
  JPX · 2026/3/2
• Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34
  Market Newswire · 2026/9/16
• Rating change
  HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
  Benzinga · 2026/8/12
• Rating change
  A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $90
  Market Newswire · 2026/9/16
• Rating change
  J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76
  Market Newswire · 2026/8/17
• Rating change
  Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $91
  Market Newswire · 2026/7/10
• Is NVIDIA (NVDA.US) facing renewed resistance as its stock price hits new highs? Amid surging demand for both GPUs and Vera CPUs, a director has cashed out $300 million in a major sell-off.
  Zhitong Finance · 2026/9/23
• H.C. Wainwright Remains a Buy on Vera Therapeutics (VERA)
  TipRanks · 2026/10/1
• H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90
  Market Newswire · 2026/10/1
• Rating change
  A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $100
  Market Newswire · 2026/8/11
• Rating change
  LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90
  Market Newswire · 2026/7/11
• Rating change
  H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90
  Market Newswire · 2026/8/12
• Rating change
  Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
  Market Newswire · 2026/8/13
• NVIDIA's stock hits a new high but faces resistance again? As demand for GPUs and Vera CPUs surges on two fronts, a Director has cashed out $300 million.
  Zhitong Finance · 2026/9/23
• Rating change
  TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $78
  Market Newswire · 2026/8/31
• Company notice
  Takeda Pharmaceutical: Regarding the U.S. Food and Drug Administration (FDA) approval of MIMRYLO (rusfertide), which has the potential to usher in a paradigm shift in the treatment of polycythemia vera.
  JPX · 2026/8/29
• Company notice
  Takeda Pharmaceutical: Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
  JPX · 2026/8/29
• Company notice
  Takeda Pharmaceutical: Takeda Announces U.S. FDA Accepts NDA and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
  JPX · 2026/3/2

Headlines are aggregated automatically and are not independently verified or edited by our team.